- Company
- 'Champix' sales rebounded 13% in one year
- by Kim, Jin-Gu Jun 3, 2020 06:25am
- Pfizer's anti-smoking supplement Champix (Varenicline) has been successful in rebounding sales. It increased by 13% compared to the first quarter of last year. It is an analysis that it benefited from winning the patent dispute with generics. According to the drug analysis agency IQVIA on the 29th, the sales of Champix in the first quar
- Policy
- MFDS & FDA have different NDMA’s follow-up measures
- by Lee, Jeong-Hwan Jun 2, 2020 09:13pm
- The domestic pharmaceutical industry has pointed out that the MFDS and the US Food and Drug Administration (FDA) have made unusually different follow-up measures over NDMA detection Metformin. The MFDS caused an immediate and irreversible damage to pharmaceutical companies by disposing of manufacturing and sales prohibition along with the ful
- Policy
- Janssen to import Ultracet as Hyangnam factory closes
- by Lee, Tak-Sun Jun 2, 2020 06:09am
- As Janssen Korea is closing down its Hyangnam factory next year, the locally manufactured pain reliever Ultracet fast-acting tablet (acetaminophen plus tramadol hydrochloride) would be imported, instead. However, the extended release tablet form of the drug, developed in Korea, would be manufactured by Handok. A pharmaceutical industr
- Company
- New anticancer drugs by Bayer have been approved in Korea
- by Eo, Yun-Ho Jun 2, 2020 06:09am
- Two new drugs of Bayer's anticancer drugs will enter the domestic market. Androgen Receptor Inhibitor (ARi), Nubeqa (Darolutamide), treatment for nmCRPC and Orbital Selective Tropomyosin Receptor Kinase (TRK) inhibitor, Vitrakvi (Larotretinib) was recently approved by the MFDS. Nubeqa is an androgen receptor inhibitor with a unique chem
- Policy
- The emergency introduction of Remdesivir was confirmed
- by Lee, Tak-Sun Jun 2, 2020 06:09am
- The government urgently introduced Gilead's 'Remdesivir' as a cure for COVID-19. Accordingly, the MFDS is planning to go through a special import procedure. Eun-kyung Jung, Head of the Central Disease Control Headquarters, said at the regular briefing on the 29th that the Central Clinical Committee on 28th suggested the need for the introd
- Company
- Prescription drop amid COVID-19 finally emerges in April
- by Chon, Seung-Hyun Jun 2, 2020 06:09am
- The outpatient prescription volume in April has dropped by 10 percent against the same month last year. The outcome contrasts to this year’s first quarter prescription volume showing an increase against last year. Although the COVID-19 confirmed case curve in Korea seems to have gone down from April, the prescription volume shrunk even worse.
- Policy
- Pfizer's non-steroidal eczema, under phase III in Korea
- by Lee, Tak-Sun Jun 1, 2020 06:20am
- A non-steroidal ointment that can be used for eczema in children is under clinical trial for domestic introduction. Pfizer's Crisaborole is a drug sold in the United States under the name of 'Eucrisa' after it was approved by the US in 2016. The MFDS approved a multinational clinical trial phase III for Pfizer’s Crisaborole on the 29th of
- Policy
- Mabthera coverage extended and Strensiq newly listed
- by Kim, Jung-Ju Jun 1, 2020 06:20am
- Healthcare reimbursement would be granted on AbbVie Korea’s adult psoriasis treatment Skyrizi prefilled syringe (risankizumab) and Handok’s rare disease treatment Strensiq Injection (asfotase alfa) with new reimbursement standards. Korea’s Ministry of Health and Welfare (MOHW) announced the finalized changes in the revised Healthcare
- Company
- Ilyang’s Supect were approved for phase III in Russia
- by Lee, Seok-Jun Jun 1, 2020 06:19am
- Ilyang announced on the 28th that its domestically developed new drug, Supect, will be conducting phase III clinical trials in Russia for the purpose of treating COVID-19. According to the company, Supect received phase III approval of 'COVID-19 treatment' from the Russian government under the supervision of R-Pharm, the No. 1 company in t
- Policy
- Hanmi, applied for permission for Xoterna's generic drug
- by Lee, Tak-Sun Jun 1, 2020 06:19am
- Hanmi is expanding its inhaler business for respiratory diseases such as bronchial asthma and chronic obstructive pulmonary disease (COPD). In 2014, Fluterol, generic for GSK's asthma treatment was first introduced in Korea, and recently, the COPD treatment Xoterna (Korea Sandos) is also targeting the market. According to the industry
